Physician profile
Rohit Reejsinghani
NPI 1427219104
$1,240.53
in general payments reported to CMS, 2019-2025
22 companies · $77.80 in 2025
The $77.80 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $20.39 · 2021: $225 · 2022: $125 · 2023: $35.00 · 2024: $565 · 2025: $77.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $678.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $677.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $249.56 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $175.00 | 2019 | |
| Janssen Pharmaceuticals, INC | $133.90 | 2024 | Spravato |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.00 | 2021 | |
| Averitas Pharma INC. | $68.42 | 2024 | Qutenza |
| Shield Therapeutics INC | $63.62 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $52.11 | 2023-2024 | Quviviq |
| Glaxosmithkline, LLC. | $48.17 | 2024 | Arexvy |
| Amgen INC. | $43.51 | 2024 | Otezla, Repatha |
| Lilly USA, LLC | $43.47 | 2024 | Mounjaro, Zepbound |
| Abbvie INC. | $43.46 | 2024-2025 | |
| Exact Sciences Corporation | $34.23 | 2025 | The Cologuard Plus Collection Kit |
| Viiv Healthcare Company | $24.48 | 2024 | Apretude |
| Merck Sharp & Dohme LLC | $23.39 | 2024 | Gardasil, M-M-R II, Capvaxive |
| Eisai INC. | $20.39 | 2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.07 | 2024 | Rexulti |
| Verastem, INC. | $17.79 | 2019 | |
| Bausch Health US, LLC | $17.47 | 2024 | Aplenzin, Wellbutrin |
| Takeda Pharmaceuticals U.S.A., INC. | $16.87 | 2024 | Trintellix |
| Lundbeck LLC | $15.76 | 2024 | Vyepti |
| Novartis Pharmaceuticals Corporation | $14.97 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.89 | 2024 | Airsupra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rohit Reejsinghani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.